Last Updated : June 18, 2020
Details
FilesGeneric Name:
ixekizumab
Project Status:
Complete
Therapeutic Area:
Ankylosing spondylitis
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Taltz
Project Line:
Reimbursement Review
Project Number:
SR0630-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.
Submission Type:
Initial
Fee Schedule:
Schedule B
Indications:
Ankylosing spondylitis
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient input posted | August 01, 2019 |
| Patient group input closed | September 23, 2019 |
| Clarification:
- Patient input submission received from Arthritis Consumer Experts, Canadian Arthritis Patient Alliance and Canadian Spondylitis Association |
|
| Patient input summary sent for review to patient input groups | October 15, 2019 |
| Patient group comments on input summary closed | October 22, 2019 |
| Clarification:
- Patient input summary feedback received |
|
| Submission received | September 20, 2019 |
| Submission accepted | October 08, 2019 |
| Clarification:
- Submission was not accepted for review on 4 Oct 2019 - Revised category 1 requirements received on 7 Oct 2019 |
|
| Review initiated | October 09, 2019 |
| Draft CADTH review report(s) sent to sponsor | December 23, 2019 |
| Comments from sponsor on draft CADTH review report(s) received | January 09, 2020 |
| CADTH review team's comments on draft CADTH review report(s) sent to sponsor | February 06, 2020 |
| Canadian Drug Expert Committee (CDEC) meeting | February 19, 2020 |
| CDEC recommendation sent to sponsor and drug plans | March 03, 2020 |
| Embargo period ended | March 17, 2020 |
| CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plans | March 24, 2020 |
| CDEC Final Recommendation posted | March 27, 2020 |
| Redaction requests from sponsor on draft CADTH review report(s) received | April 07, 2020 |
| Redacted CADTH review report(s) sent to sponsor and drug plans | April 20, 2020 |
| Validation of redacted CADTH review report(s) received | - |
| Final CADTH review report(s) posted | May 22, 2020 |
Files
Last Updated : June 18, 2020